MAK HILL Publications Research Journal of Medical Sciences

Review Article
doi: 10.36478/makrjms.2024.11.136.141

OPEN ACCESS

Key Words
Dysbiosis, gut microbiota, human health, microbiome, therapeutic interventions

Corresponding Author
Megha R. Raju,
Department of General Medicine, Sree Mookambika Institute of Medical Sciences, Kanyakumari, Tamil Nadu, India

Author Designation
[1]Post Graduate
[2]Professor

Received: 12 August 2024
Accepted: 13 October 2024
Published: 16 October 2024

Citation: Megha R. Raju and M.K. Suresh, 2024. A Review on Exploring the Role of Gut Microbiota in Metabolic Disorders. Res. J. Med. Sci., 18: 136-141, doi: 10.36478/makrjms.2024.11.136.141

A Review on Exploring the Role of Gut Microbiota in Metabolic Disorders

[1]Megha R. Raju and [2]M.K. Suresh

[1,2]Department of General Medicine, Sree Mookambika Institute of Medical Sciences, Kanyakumari, Tamil Nadu, India

ABSTRACT
The study investigates the complex connection between health and the human gut flora. It examines the functions of the gut microbiota in immunological responses, digestion, metabolism and general health. The diversity and makeup of gut microbial communities are covered in the review, with a focus on their symbiotic interaction with the host. It also looks at the connections between diseases including metabolic disorders and inflammatory bowel diseases and gut dysbiosis, or microbial imbalance. The review focuses on research approaches that help us better understand the function of the gut microbiota, such as metagenomics and metabolomics. It also looks at how the gut microbiota is shaped by outside variables like nutrition and antibiotic use. Probiotics and faecal microbiota transplantation are two examples of possible therapeutic approaches covered in the paper, which points to the potential for personalized medicine in the future. The review seeks to improve knowledge of the gut microbiota's function in health by combining current findings and offering recommendations for further study and treatment.

INTRODUCTION

Bacteria, viruses, fungi and archaea make up the complex ecology known as the gut microbiota, of which the bacterial component has been researched the most. This microbial population engages in a variety of interactions with the host, impacting immune system development and function, nutrition metabolism and even behaviour through the gut-brain axis. Serious host diseases like cancer, inflammatory bowel disease and metabolic disorders have been linked to disruptions in the microbiome. Clarifying the gut microbiota's involvement in human health and disease requires an understanding of its makeup and function. Human health is significantly impacted by the gut microbiota through a variety of processes. Its basic functions include nutritional metabolism, including the fermentation of complex sugars and dietary fibres that host enzymes cannot break down. Short-chain fatty acids (SCFAs), such as acetate, propionate and butyrate, are produced during this process and are essential for preserving the integrity of the gut barrier and controlling immunological responses. They also provide colonic epithelial cells with energy[1]. Additionally, the gut microbiota aids in the production of vital vitamins, such as vitamin K and several B vitamins, which are critical for a number of physiological functions, including energy metabolism and blood coagulation[2]. The complex relationship between the gut microbiota and central nervous system is further highlighted by the fact that microbial metabolites, including neurotransmitters and neuroactive chemicals made in the gut, can affect behaviour and brain function through the gut-brain axis[3]. This review attempts to give a thorough overview of the gut microbiota's functions and implications for disease causation and therapy, given its many roles in human health. It will go over the gut microbiota's makeup and role, as well as how it affects host metabolism and physiology and contributes to the development of different diseases.

The Gut Microbiota's Metabolic Activity: The number of bacteria that live in the human body has been adjusted to 3·8·1013, which is the same number of human cells. Together with Proteobacteria and Actinobacteria, the gram-positive Firmicutes and gram-negative Bacteroidetes comprise the great majority, accounting for 60-80% and 20-30% of the entire GM, respectively[4]. Numerous bacterial species in the microbiota have been demonstrated to provide protection against metabolic disorders as type-2 diabetes (T2D), obesity and metabolic syndrome (MetS). Furthermore, in obese individuals, a lower microbial diversity, hence a lower metagenomic makeup, increases the risk of weight gain, adiposity, insulin resistance and inflammation compared with those who show a higher number of genes[5]. The GM is involved in the production of secondary bile acids (BAs)[6] and protein catabolism, degradation of xenobiotics, production of water-soluble vitamins, but it is gaining relevance not only for its crucial role in the development and maintenance of proper functioning of innate and adaptive immunity and gut-associated lymphoid tissue (GALT), but also for its implication in the process of energy extraction from otherwise indigestible foods. Up to 90% of all bacteria in the gut belong to the two dominating phyla, Firmicutes and Bacteroidetes[7]. There are thousands of distinct species within these phyla and each person has a distinct "microbiota fingerprint-a" combination of microbial species[8]. Due of variables like age, nutrition, location and host genetics, many species show significant individual variability. Primary pathogens, including species like Campylobacter jejuni, Salmonella enterica, Vibrio cholera, Escherichia coli and Bacteroides fragilis, are also found in the human colon in addition to taxa from the phyla Firmicutes and Bacteroidetes, although they are not very common (0.1% or less of the total gut microbiome)[9]. In addition to this longitudinal difference, there is an axial differential between the intestinal mucosa and lumen. While the most common luminal microbial genera (found in stool) are Bacteroides, Bifidobacterium, Streptococcus, Enterobacteriacae, Enterococcus, Clostridium, Lactobacillus and Ruminococcus, the most common mucosa and mucus-associated genera (found in the mucus layer and epithelial crypts of the small intestine) are Clostridium, Lactobacillus, Enterococcus and Akkermansia. Comprehensive profiling of the composition of the gut microbiota at different taxonomic levels has been made possible by recent developments in high-throughput sequencing technologies, such as metagenomics and 16S rRNA gene sequencing. Significant inter-individual variation in gut microbial communities, known as microbial "enterotypes," has been found in these investigations. These variations are typified by variations in the relative abundance of important bacterial species[10]. Another quickly developing area of study on the gut microbiota is metabolomics, which assesses tiny chemicals linked to the interaction between bacterial and human metabolism and has consequences for both health and illness. The strongest evidence that can show the strongest correlation between healthy and pathological states is now provided by composite data from the gut microbiota and the metabolome. But with to developments in large-scale sequencing, machine learning, a branch of artificial intelligence (AI), can be used to analyse vast amounts of data on microbes and make diagnoses of various diseases[11].

Gut Microbiota as a Diabetes Diagnostic Prediction or Prognostic Biomarker: Taxonomic analysis revealed a list of microbial risk markers that included moderate dysbiosis, a decrease in butyrate producers, an increase in a variety of opportunistic pathogens and an enrichment of microbial functions linked to resistance to oxidative stress and sulphate reduction. Additionally, a specific gut metagenomic linkage group associated with T2D risk was established[12]. Inter-individual differences in the GM may potentially explain varying reactions to dietary approaches in addition to being predictive of disease progression, according to recent studies. The observed inter-individual variability in postprandial blood glucose from the same meal may be due to variances in GM, according to precision nutrition studies, which repeatedly demonstrate that each person's GM composition is essential for customising dietary recommendations for each patient. The PREVIEW trial, the largest intervention to date in overweight or obese people with pre-diabetes who were following an 8-week low energy diet (LED) to lose weight, demonstrated that the baseline characteristics of the GM might predict the reduction in body fat during the LED[13]. In a different study, a cohort of 800 participants showed a large inter-individual variability in post-meal hyperglycemia that could be predicted by particular clinical and microbial variables. This finding was confirmed in a second cohort of 100 people[14]. Furthermore, in over 1000 twins and unrelated individuals, the PREDICT study demonstrated that the GM composition accounts for 7·5% of postprandial triglyceride levels, 6·4% of postprandial glycaemia and 5·8% of postprandial C-peptide levels without controlling for any other individual characteristics. This finding was further confirmed in a US cohort of 100 people[15].

Factors Influencing Gut Microbiota Composition: The composition and stability of the gut microbiota are shaped by a myriad of factors, both intrinsic and extrinsic to the host. Diet exerts a profound influence on gut microbiota composition, with dietary components serving as substrates for microbial metabolism and growth. For instance, high-fiber diets promote the growth of fiber-degrading bacteria, such as members of the Bacteroidetes phylum, whereas diets rich in saturated fats may favor the expansion of pro- inflammatory microbial taxa[1]. In addition to diet, host genetics play a role in shaping the gut microbiota composition. Twin studies have demonstrated that monozygotic twins exhibit more similar gut microbial profiles compared to dizygotic twins, indicating a genetic component to gut microbiota composition[16]. Furthermore, environmental factors, such as antibiotic exposure, stress and mode of birth (vaginal delivery vs. cesarean section), can significantly impact the assembly and development of the gut microbiota early in life[17]. Understanding the dynamic interplay between these factors is essential for unraveling the complex mechanisms governing gut microbiota composition and its implications for host health and disease. Understanding the dynamic interplay between these factors is essential for unraveling the complex mechanisms governing gut microbiota composition and its implications for host health and disease.

Therapeutic Approaches Targeting Gut Microbiota: The dynamic and modifiable nature of the gut microbiota has spurred interest in developing therapeutic interventions aimed at restoring microbial balance (eubiosis) and ameliorating dysbiosis-associated diseases. These approaches include the use of probiotics, prebiotics, postbiotics, fecal microbiota transplantation (FMT) and dietary interventions, each offering unique mechanisms for manipulating the gut microbiota and improving host health.

Prebiotics: Probiotics are live microorganisms that, when administered in adequate amounts, confer health benefits to the host. Commonly used probiotic strains belong to the genera Lactobacillus and Bifidobacterium, which are known for their ability to modulate immune function, gut microbiota composition, improve gut barrier integrity and inhibit the growth of pathogenic bacteria. Probiotic administration is suggested to restore microbial dysbiosis and maintain intestinal microbial balance by occupying host tissue and preventing colonization of pathogenic bacteria. Lactobacillus has been considered an option for preventing antibiotic-associated diarrhea in children[18]. For instance[19], reported that Lactobacillus casei inhibits growth of Helicobacter pylori and the co-colonization of Lactobacillus rhamnosus GG and Bifdobacterium lactis Bb12 promoted innate immune responses to human rotavirus. Probiotic supplementation has been shown in clinical studies, to be effective in preventing and treating various gastrointestinal disorders, such as antibiotic-associated diarrhea, irritable bowel syndrome (IBS), IBD and allergies[18].

Diabetes and Fecal Microbiota Transplantation (FMT): Another strategy to harness the microbiota as an adjuvant strategy in the treatment of diabetes is FMT, also known as stool transplantation: the transfer of stools from a healthy donor into another subject's gastrointestinal tract, aiming to change the recipient's GM gaining health benefit[20]. For instance, FMT is currently one of the most successful therapy for

recurrent and refractory Clostridium Difficile Infection (CDI)[21], even in immunodepressed[22] or with underlying comorbidities patients. Given its successful exploitation, researcher and clinicians are considering its potential beyond the application in CDI, to treat other medical conditions implying dysbiosis. Emerging evidence is consistently showing that FMT may not only improve insulin sensitivity, but also alter the natural course of type I diabetes by modulating autoimmunity. Plenty of preclinical data have been published in the last years and, despite model-related difference, have consistently shown the advantage of FMT in the improvement of insulin resistance, weight gain, cardio metabolism, and liver steatosis. Human data are finally becoming available and confirming the enormous amount of pre-clinical data publish in the last decade. A recent study compared the effects of FMT from donors who underwent bariatric surgery and donors with MetS. While a reduction in inflammatory indices was observed in the recipients from bariatric patients, a decrease in insulin sensitivity and an increase in secondary BAs was displayed in those transplanted from metabolic patients[23], highlighting the fact that different conditions may benefit in different way from FTM. Currently, several Phase 1 and 2 clinical trials are studying how harnessing the microbiota could benefit patients affected by obesity, T2D and MetS (Table 2). The field is eagerly awaiting results, but the published results so far are promising. A study published in the 2019 (NCT01765517) has shown the benefit of a multi-strain probiotic supplementation over 6 months as a monotherapy in decreasing HOMA-IR in T2D patients[24]. Another study (NCT03100162) has shown the beneficial dose -dependent effects of a lyophilizate powder containing live multispecies probiotic bacteria on cardiometabolic parameters and gut permeability of obese post-menopausal women[25]. As demonstrated by other studies showing only a modest effect of GM manipulation on insulin resistance in T2D[26], it is clear now that success of microbial modulation depends on the tested strains, on its composition and diversity, on the patients pre-existing microbial diversity and his genetic fingerprint. However, there are some risks related to FMT that should be taken into account.

Future Directions and Challenges: As we look to the future, several key areas of focus and challenges emerge, including the need for further mechanistic understanding, harnessing the therapeutic potential of the microbiota and addressing ethical considerations. While considerable progress has been made in characterizing the composition and function of the gut microbiota, many questions remain regarding the underlying mechanisms driving microbiota-host interactions and their implications for health and disease. Elucidating the molecular pathways and signaling networks involved in microbiota-mediated effects on host physiology will be critical for developing targeted interventions and precision medicine approaches. Exploiting the therapeutic potential of the gut microbiota represents a promising avenue for preventing and treating a wide range of diseases. However, translating microbiota-based interventions from bench to bedside poses significant challenges, including standardization of protocols, identification of optimal microbial consortia and ensuring safety and efficacy in diverse patient populations. Furthermore, personalized approaches that consider individual variations in gut microbiota composition and function will be essential for maximizing therapeutic outcomes. As the field of microbiota-based therapeutics continues to advance, ethical considerations surrounding the manipulation of the human microbiota warrant careful attention. Questions regarding informed consent, privacy rights and the long-term consequences of microbial interventions on host health and ecosystem stability must be addressed to ensure responsible and equitable implementation of microbiota-based therapies. Additionally, efforts to promote diversity and inclusivity in microbiota research and therapy development are needed to mitigate potential disparities in access and outcomes. Advancements in high-throughput sequencing, metagenomics, metabolomics and computational modeling have revolutionized our ability to study the gut microbiota and its functional dynamics. Continued investment in technological innovation will be crucial for overcoming existing limitations, such as the inability to culture the majority of gut microbes and the challenges associated with studying microbial-host interactions in complex ecosystems. Integration of multi-omics data and development of predictive modeling approaches will further enhance our understanding of microbiota-host dynamics and facilitate the design of personalized interventions.

CONCLUSION

The gut microbiota plays a crucial role as a mediator of host-microbe interactions by influencing immune system function, food metabolism and the creation of bioactive chemicals through a variety of metabolic activities. Our knowledge of the gut microbiota has significantly increased in recent years due to developments in metagenomics, high-throughput sequencing and systems biology, which have shown its enormous diversity and functional complexity. The pathophysiology of many diseases, including as obesity, inflammatory bowel disease, allergies and autoimmune disorders, has been linked to dysbiosis of

the gut microbiota, which is defined by changes in microbial composition and activity. These discoveries have led to an increase in interest in creating therapeutic therapies that target the gut microbiota, including dietary changes, faecal microbiota transplantation, probiotics, prebiotics and postbiotics. Although there are still obstacles in putting these discoveries into clinical practice, these strategies offer encouraging paths for modifying the gut microbiota and enhancing host health. Future studies will concentrate on clarifying the molecular mechanisms underlying interactions between the microbiota and the host, utilizing the microbiome's therapeutic potential for personalized medicine and tackling the moral dilemmas associated with microbiota-based therapies. We can fully utilise the gut microbiota as a novel target for illness prevention and therapy by embracing interdisciplinary collaboration and utilising technological innovation. Recently, the relationship between GM and inflammation, hyperinsulinemia, metabolic-associated fatty liver disease (MAFLD) and diabetes has been linked to intestinal ecology in the metabolic syndrome. Numerous findings have been made about the modulation of the gut-liver axis and GM in diabetes. The therapeutic effectiveness of probiotic supplementation in the treatment of diabetes and its complications is also the subject of several ongoing trials. To illustrate a potential therapeutic role of GM modulation with prebiotics and probiotics in diabetes and MAFLD, we identified GM as a novel predictive biomarker in diabetes and suggested that more research be done in the future.

REFERENCES

1. Holscher, H.D., 2017. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes, 8: 172-184.
2. Lai, Y., H. Masatoshi, Y. Ma, Y. Guo and B. Zhang, 2022. Role of Vitamin K in Intestinal Health. Front. Immunol., Vol. 12 .10.3389/fimmu.2021.791565.
3. Morais, L.H., H.L. Schreiber and S.K. Mazmanian, 2021. The gut microbiota–brain axis in behaviour and brain disorders. Nat. Rev. Microbiol., 19: 241-255.
4. Pitocco, D., M. Di Leo and L. Tartaglione, et al., 2020. The role of gut microbiota in mediating obesity and diabetes mellitus. Eur Rev Med Pharmacol Sci., 24: 1548-1562.
5. Le Chatelier, E., T. Nielsen and J. Qin, *et al.,* 2013. Richness of human gut microbiome correlates with metabolic markers. Nature., 500: 541-546.
6. Gadaleta, R.M., M. Cariello, L. Crudele and A. Moschetta, 2022. Bile Salt Hydrolase-Competent Probiotics in the Management of IBD: Unlocking the “Bile Acid Code”. Nutrients, Vol. 14 .10.3390/nu14153212
7. Stojanov, S., A. Berlec and B. Štrukelj, 2020. The Influence of Probiotics on the Firmicutes /Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease. Microorganisms, Vol. 8 .10.3390/microorganisms8111715.
8. Koppel, N. and E.P. Balskus, 2016. Exploring and Understanding the Biochemical Diversity of the Human Microbiota. Cell Chem. Biol., 23: 18-30.
9. Jandhyala, S.M., R. Talukdar, C. Subramanyam, H. Vuyyuru, Sasikala M, Reddy DN 2015. Role of the normal gut microbiota. World J. Gastroenterol., Vol. 21 .10.3748/wjg.v21.i29.8787.
10. Durazzi, F., C. Sala, G. Castellani, G. Manfreda, D. Remondini and A.D. Cesare, 2021. Comparison between 16S rRNA and shotgun sequencing data for the taxonomic characterization of the gut microbiota. Sci. Rep., Vol. 11 .10.1038/ s41598-021-82726-y.
11. Isiaka, A.B., V.N. Anakwenze, C.R. Ilodinso, C.G. Anaukwu, C.M-V. Ezeokoli and S.M. Noi, *et al.,* 2024. Harnessing Artificial Intelligence for Early Detection and Management of Infectious Disease Outbreaks. Int. J. Inno. Res. and Dev., 13: 52-65.
12. Qin, J., Y. Li, Z. Cai, S. Li and J. Zhu *et al.,* 2012. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature, 490: 55-60.
13. Jian, C., M.P. Silvestre, D. Middleton, K. Korpela and E. Jalo *et al.,* 2022. Gut microbiota predicts body fat change following a low-energy diet: A PREVIEW intervention study. Genome Med., Vol. 14 .10.1186/s13073-022-01053-7.
14. Zeevi, D., T. Korem, N. Zmora, D. Israeli and D. Rothschild *et al.*, 2015. Personalized Nutrition by Prediction of Glycemic Responses. Cell, 163: 1079-1094.
15. Berry, S.E., A.M. Valdes, D.A. Drew, F. Asnicar and M. Mazidi *et al.,* 2020. Human postprandial responses to food and potential for precision nutrition. Nat. Med., 26: 964-973.
16. Yang, J., S. Yao, K. Cheng, L. Xu and L. Hou *et al.*, 2020. Comparison of Meconium Microbiome in Dizygotic and Monozygotic Twins Born by Caesarean Section (CS). Front. Microbiol., Vol. 11 .10.3389/fmicb.2020.01139.
17. Bolte, E.E., D. Moorshead and K.M. Aagaard, 2022. Maternal and early life exposures and their potential to influence development of the microbiome. Genome Med., Vol. 14 .10.1186/s13073-021-01005-7.
18. Kopacz, K. and S. Phadtare, 2022. Probiotics for the Prevention of Antibiotic-Associated Diarrhea. Healthcare, Vol. 10 .10.3390/healthcare10081450.
19. Liang, D., R.K.K. Leung, W. Guan and W.W. Au, 2018. Involvement of gut microbiome in human health and disease: Brief overview, knowledge gaps and research opportunities. Gut Pathog., 10: 1-9.

20. Gupta, A. and S. Khanna, 2017. Fecal Microbiota Transplantation. JAMA, Vol. 318 .10.1001 /jama.2017.6466.
21. Svensson, C.K., F. Cold, I. Ribberholt, M. Zangenberg, H.C. Mirsepasi-Lauridsen, A.M. Petersen and M. Helms, 2022. The Efficacy of Faecal Microbiota Transplant and Rectal Bacteriotherapy in Patients with Recurrent Clostridioides difficile Infection: A Retrospective Cohort Study. Cells, Vol. 11 .10.3390/ cells11203272.
22. Luo, Y., E.N. Tixier and A.M. Grinspan, 2020. Fecal Microbiota Transplantation for Clostridioides difficile in High-Risk Older Adults Is Associated with Early Recurrence. Digestive Dis. Sci., 65: 3647-3651.
23. de Groot, P., T. Scheithauer, G.J. Bakker, A. Prodan and E. Levin *et al.,* 2020. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. Gut, 69: 502-512.
24. Sabico, S., A. Al-Mashharawi, N.M. Al-Daghri, K. Wani and O.E. Amer *et al.*, 2019. Effects of a 6-month multi-strain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: A randomized, double-blind, placebo-controlled trial. Clin. Nutr., 38: 1561-1569.
25. Szulinska, M., I. Loniewski, S.V. Hemert, M. Sobieska and P. Bogdanski, 2018. Dose-Dependent Effects of Multispecies Probiotic Supplementation on the Lipopolysaccharide (LPS) Level and Cardiometabolic Profile in Obese Postmenopausal Women: A 12-Week Randomized Clinical Trial. Nutrients, Vol. 10 .10.3390/nu1006077 .
26. Kobyliak, N., T. Falalyeyeva, G. Mykhalchyshyn, D. Kyriienko and I. Komissarenko, 2018. Effect of alive probiotic on insulin resistance in type 2 diabetes patients: Randomized clinical trial. Diabetes and Metab. Syndrome: Clin. Res. and Rev., 12: 617-624